Safety Study of ABT-263 in Combination With Gemzar (Gemcitabine) in Subjects With Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

November 30, 2011

Study Completion Date

November 30, 2011

Conditions
Solid Tumors
Interventions
DRUG

ABT-263

"150mg of ABT-263 is taken orally once daily on Days 1-3 and Days 8-10 out of each 21 day cycle.~325 mg of ABT-263 is taken orally once daily on days 1-3, 8-10, 15-17 out of each 28 day cycle.~This is a dose escalation study, therefore the dose of ABT-263 will change throughout the study."

DRUG

gemcitabine

Gemcitabine 1000 mg/m2 will be given by intravenous infusion on Day 1 and Day 8 of each 21 day cycle. Gemcitabine 1000 mg/m2 will be given by intravenous infusion on days 1, 8 and 15 of each 28 day cycle.

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

AbbVie

INDUSTRY